Share on StockTwits

Cross Country Healthcare (NASDAQ:CCRN) Director Emil Hensel sold 9,310 shares of the stock on the open market in a transaction dated Wednesday, July 30th. The shares were sold at an average price of $7.22, for a total transaction of $67,218.20. Following the completion of the sale, the director now directly owns 100,608 shares in the company, valued at approximately $726,390. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Shares of Cross Country Healthcare (NASDAQ:CCRN) traded up 0.14% on Wednesday, hitting $7.36. The stock had a trading volume of 93,227 shares. Cross Country Healthcare has a 52 week low of $5.17 and a 52 week high of $11.54. The stock has a 50-day moving average of $6.60 and a 200-day moving average of $7.85. The company’s market cap is $229.0 million.

Cross Country Healthcare (NASDAQ:CCRN) last announced its earnings results on Wednesday, May 7th. The company reported ($0.03) EPS for the quarter, missing the Thomson Reuters consensus estimate of ($0.01) by $0.02. The company had revenue of $118.10 million for the quarter, compared to the consensus estimate of $120.21 million. During the same quarter in the prior year, the company posted ($0.01) earnings per share. The company’s quarterly revenue was up 7.0% on a year-over-year basis. On average, analysts predict that Cross Country Healthcare will post $0.04 earnings per share for the current fiscal year.

Several analysts have recently commented on the stock. Analysts at Zacks upgraded shares of Cross Country Healthcare from an “underperform” rating to a “neutral” rating in a research note on Thursday, July 3rd. They now have a $6.80 price target on the stock.

Cross Country Healthcare, Inc (NASDAQ:CCRN) is engaged in the healthcare staffing services business offering a suite staffing and outsourcing services to the healthcare market.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.